Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Business
  • Published:

The quiet rise of the clinical contractor

More and more drug trials are being farmed out to contractors, but who's benefiting from the change? Meredith Wadman investigates.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Related links

Related links

Related links in Nature Research

Can super-antibody drugs be tamed?

London's disastrous drug trial has serious side effects for research

Related external links

Tufts Center for the Study of Drug Development

Parexel

PRA International

Association of Clinical Research Organisations (ACRO)

Rights and permissions

Reprints and permissions

About this article

Cite this article

The quiet rise of the clinical contractor. Nature 441, 22–23 (2006). https://doi.org/10.1038/441022a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/441022a

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing